- Company
- Opdivo approved as 1st-line Tx for urothelial cell carcinoma
- by Hwang, Byung-woo Jul 23, 2024 05:48am
- Ono Pharma Korea and BMS Korea announced on the 22nd that Opdivo (nivolumab) has been additionally approved by the Ministry of Food and Drug Safety as a first-line treatment for urothelial cell carcinoma (UCC). The new indication is for the first-line treatment of unresectable or metastatic urothelial cell carcinoma in combination with ci
- Company
- "Trodelvy gives new hope for triple-negative breast cancer"
- by Son, Hyung-Min Jul 23, 2024 05:48am
- Triple-negative breast cancer refers to a breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is a rare cancer that accounts for about 12-15% of all breast cancer. This cancer tends to be aggressive and has a high risk of metastasis and recurrence, leading
- Company
- Eisai reports degrowth for 3 consecutive years
- by Hwang, Byung-woo Jul 23, 2024 05:47am
- Eisai Korea has recorded a decline in sales of its flagship products, including its anti-cancer drug Lenvima (lenvatinib), for 3 consecutive years since 2020. The company has not seen a clear rebound since experiencing a significant drop in sales in 2022. The company’s JAK inhibitor Jyseleca (filgotinib), which was listed for reimbursement
- Company
- Atopic dermatitis drugs get expanded indication for infants
- by Eo, Yun-Ho Jul 23, 2024 05:47am
- New atopic dermatitis drugs are currently being considered for expanded use in infants and young children. First, Sanofi Korea's 'Dupixent (dupilumab)' will be reimbursed for treating infants aged 6 months beginning next month. The company has recently concluded the drug price negotiation, and on July 19th, Dupixent was incorporated into
- Company
- Hyperlipidemia Drug Leqvio’s nears market entry in KOR
- by Hwang, Byung-woo Jul 23, 2024 05:47am
- Novartis’s Leqvio’s (Inclisiran), is preparing to enter Korea’s market as the first siRNA therapy, armed with its convenience of twice a year administration. However, in a situation where there are already many treatments for hyperlipidemia available on the market, the high cost of Leqvio compared to existing treatments may
- Company
- Efforts to develop a new drug for dry eye syndrome continue
- by Son, Hyung-Min Jul 22, 2024 05:51am
- The domestic and foreign pharmaceutical industry is intent on developing new drugs for dry eye syndrome, making reattempts despite the failure of their clinical trials. Hanall Biopharma is conducting its third Phase III clinical trial, and Huons has started clinical trials with a new drug candidate. In the U.S., Aldeyra is reattempting FDA appro
- Company
- The 1st cardiomyopathy drug 'Camzyos' lands in hospitals
- by Eo, Yun-Ho Jul 22, 2024 05:50am
- 'Camzyos,' under consideration for insurance reimbursement listing, is becoming available for prescriptions at medical centers. Industry sources said that Bristol Myers Squibb (BMS) Korea's Camzyos (mavacamten), a new drug used to treat obstructive hypertrophic cardiomyopathy (oHCM), has passed the drug committees (DC) of 'Big 5' general
- Company
- 'Prostate cancer market leader' Astellas eyes on KRW 300 bil
- by Hwang, Byung-woo Jul 19, 2024 05:48am
- Astellas Pharma Korea's sales rebounded within four years due to the sales growth of Xtandi (enzalutamide), a prostate cancer drug. In addition to its leading product, Prograf (tacrolimus), showing strong sales, the company is expected to continue to generate sales growth when Padcev (enfortumab vedotin), an ADC for the treatment of urothelia
- Company
- 'Adtralza' lands in general hospitals in KOR
- by Eo, Yun-Ho Jul 19, 2024 05:47am
- 'Adtralza,' the treatment of atopic dermatitis, is quickly establishing presence in the market. Industry sources said that LEO Pharma Korea’s Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing interleukin-13 (IL-13), has passed the drug committees (DC) of tertiary general hospitals, in
- Company
- Forxiga generics, Jardiance·Envlo, surpass original drug
- by Kim, Jin-Gu Jul 18, 2024 05:49am
- The market for SGLT-2 inhibitors used to treat diabetes is shifting due to advancing generics and new drugs made in South Korea. The prescription sales of Forxiga (dapagliflozin), which is set to withdraw from South Korea, have significantly dropped. In contrast, the prescription sales of Forxiga generics quickly increased, surpassing t
